Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  62 results for ""MAP Kinase Kinase 1""

Your Filters

Subject : proto-oncogene proteins p21(ras)
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

PDP1 promotes KRAS mutant colorectal cancer progression by serving as a scaffold for BRAF and MEK1.

  • Authors : Yuan M; Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510655, PR China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510655, PR China

Subjects: Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/genetics ; Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/pathology ; Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/drug therapy

  • Source: Cancer letters [Cancer Lett] 2024 Aug 10; Vol. 597, pp. 217007. Date of Electronic Publication: 2024 Jun 05.Publisher: Elsevier Science Ireland Country of Publication: Ireland NLM ID: 7600053 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.

  • Authors : Wang Z; Department of Gastrointestinal Surgery IV, Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital and Institute, Beijing, China.; Kang B

Subjects: Class I Phosphatidylinositol 3-Kinases/Class I Phosphatidylinositol 3-Kinases/Class I Phosphatidylinositol 3-Kinases/*metabolism ; Colorectal Neoplasms/Colorectal Neoplasms/Colorectal Neoplasms/*pathology ; Gene Editing/Gene Editing/Gene Editing/*methods

  • Source: Cancer science [Cancer Sci] 2021 Sep; Vol. 112 (9), pp. 3895-3910. Date of Electronic Publication: 2021 Jul 27.Publisher: Wiley Publishing on behalf of the Japanese Cancer Association Country of Publication: England NLM ID: 101168776 Publication Model: Print-Electronic

Record details

Read More Add to Saved list
×
Academic Journal

Detecting mosaic variants in patients with somatic overgrowth syndromes using cell-free circulating DNA and deep sequencing.

  • Authors : Shen W; Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA .; ARUP Institute for Clinical and Experimental Pathology, ARUP Laboratories, ARUP Laboratories, Salt Lake City, Utah, USA.

Subjects: Mosaicism*; Class I Phosphatidylinositol 3-Kinases/Class I Phosphatidylinositol 3-Kinases/Class I Phosphatidylinositol 3-Kinases/*genetics ; GTP-Binding Protein alpha Subunits/GTP-Binding Protein alpha Subunits/GTP-Binding Protein alpha Subunits/*genetics

  • Source: Journal of medical genetics [J Med Genet] 2020 Nov; Vol. 57 (11), pp. 794-796. Date of Electronic Publication: 2020 Jan 28.Publisher: British Medical Association Country of Publication: England NLM ID: 2985087R Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer.

  • Authors : Liu K; School of Medicine, Southeast University, Nanjing, Jiangsu, China.; Department of Otolaryngology Head and Neck Surgery, BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

Subjects: Drug Resistance, Neoplasm*; Biomarkers, Tumor/Biomarkers, Tumor/Biomarkers, Tumor/*metabolism ; Cetuximab/Cetuximab/Cetuximab/*pharmacology

  • Source: Molecular carcinogenesis [Mol Carcinog] 2020 Oct; Vol. 59 (10), pp. 1147-1158. Date of Electronic Publication: 2020 Aug 17.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8811105 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling.

  • Authors : Fish JE; From the Toronto General Hospital Research Institute (J.E.F., E.B., D.G., P.V.D., Z.C.), University Health Network, Canada.; Peter Munk Cardiac Centre (J.E.F.), University Health Network, Canada.

Subjects: Gain of Function Mutation*; Endothelial Cells/Endothelial Cells/Endothelial Cells/*enzymology ; Intracranial Arteriovenous Malformations/Intracranial Arteriovenous Malformations/Intracranial Arteriovenous Malformations/*genetics

  • Source: Circulation research [Circ Res] 2020 Aug 28; Vol. 127 (6), pp. 727-743. Date of Electronic Publication: 2020 Jun 17.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0047103 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Intramuscular fast-flow vascular anomaly contains somatic MAP2K1 and KRAS mutations.

  • Authors : Goss JA; Department of Plastic & Oral Surgery, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Boston, MA, 02115, USA.; Konczyk DJ

Subjects: Mutation*; Hemangioma/Hemangioma/Hemangioma/*genetics ; MAP Kinase Kinase 1/MAP Kinase Kinase 1/MAP Kinase Kinase 1/*genetics

  • Source: Angiogenesis [Angiogenesis] 2019 Nov; Vol. 22 (4), pp. 547-552. Date of Electronic Publication: 2019 Sep 05.Publisher: Springer Country of Publication: Germany NLM ID: 9814575 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7209

Record details

Read More Add to Saved list
×
Academic Journal

A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers.

  • Authors : Rao S; Laboratory of Systems Pharmacology, Boston, Massachusetts 02115; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115

Subjects: Carcinoma, Non-Small-Cell Lung/Carcinoma, Non-Small-Cell Lung/Carcinoma, Non-Small-Cell Lung/*enzymology ; Lung Neoplasms/Lung Neoplasms/Lung Neoplasms/*epidemiology ; MAP Kinase Kinase 1/MAP Kinase Kinase 1/MAP Kinase Kinase 1/*antagonists & inhibitors

  • Source: The Journal of biological chemistry [J Biol Chem] 2019 May 24; Vol. 294 (21), pp. 8664-8673. Date of Electronic Publication: 2019 Mar 11.Publisher: Elsevier Inc. on behalf of American Society for Biochemistry and Molecular Biology Country of Publication: United States NLM ID: 2985121R Publication

Record details

Read More Add to Saved list
×
Academic Journal

Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations.

  • Authors : Moon JH; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Medical Science, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.

Subjects: Class I Phosphatidylinositol 3-Kinases/Class I Phosphatidylinositol 3-Kinases/Class I Phosphatidylinositol 3-Kinases/*genetics ; Colonic Neoplasms/Colonic Neoplasms/Colonic Neoplasms/*drug therapy ; Colonic Neoplasms/Colonic Neoplasms/Colonic Neoplasms/*genetics

  • Source: British journal of cancer [Br J Cancer] 2019 Apr; Vol. 120 (9), pp. 941-951. Date of Electronic Publication: 2019 Apr 04.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.

  • Authors : Capparelli C; Department of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.; Purwin TJ

Subjects: MAP Kinase Kinase 1/MAP Kinase Kinase 1/MAP Kinase Kinase 1/*antagonists & inhibitors ; Melanoma/Melanoma/Melanoma/*drug therapy ; Neuregulin-1/Neuregulin-1/Neuregulin-1/*metabolism

  • Source: Cancer research [Cancer Res] 2018 Oct 01; Vol. 78 (19), pp. 5680-5693. Date of Electronic Publication: 2018 Aug 16.Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.

  • Authors : Stewart A; Division of Cancer Therapeutics/Division of Clinical Studies, The Institute of Cancer Research, London.; Thavasu P

Subjects: MAP Kinase Kinase 1/MAP Kinase Kinase 1/MAP Kinase Kinase 1/*antagonists & inhibitors ; Neoplasms/Neoplasms/Neoplasms/*drug therapy ; Phosphatidylinositol 3-Kinases/Phosphatidylinositol 3-Kinases/Phosphatidylinositol 3-Kinases/*genetics

  • Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2015 Jul; Vol. 26 (7), pp. 1504-10. Date of Electronic Publication: 2015 Apr 23.Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041

Record details

Read More Add to Saved list
×
  • 1-10 of  62 results for ""MAP Kinase Kinase 1""